{{chembox
| Verifiedfields = changed
| verifiedrevid = 470635612
| ImageFile = Zaprinast.svg
| ImageSize = 150
| ImageAlt = 
| IUPACName = 5-(2-Propoxyphenyl)-1''H''-[1,2,3]triazolo[4,5-d]pyrimidin-7(4''H'')-one
| OtherNames = M&B 22,948

| Section1 = {{Chembox Identifiers
| IUPHAR_ligand = 2919
| CASNo = 37762-06-4
| CASNo_Ref = {{cascite|changed|??}}
| PubChem = 5722
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5520
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 28079
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = REZGGXNDEMKIQB-UHFFFAOYSA-N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)
| SMILES = O=C1C2=C(N=NN2)NC(C3=CC=CC=C3OCCC)=N1
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GXT25D5DS0
  }}

| Section2 = {{Chembox Properties
| C=13 | H=13 | N=5 | O=2 
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}

| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound =
| Excretion =
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat =
| PregCat_AU =
| PregCat_US =
  }}
}}

'''Zaprinast''' was an unsuccessful clinical drug candidate that was a precursor to the chemically related [[PDE5 inhibitor]]s, such as [[sildenafil]] (Viagra), which successfully reached the market. It is a [[phosphodiesterase inhibitor]],<ref>{{cite journal | last1 = Choi | first1 = SH | last2 = Choi | first2 = DH | last3 = Song | first3 = KS | last4 = Shin | first4 = KH | last5 = Chun | first5 = BG | title = Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells | journal = Journal of neuroscience research | volume = 67 | issue = 3 | pages = 411–21 | year = 2002 | pmid = 11813247 | doi = 10.1002/jnr.10102 }}</ref> selective for the subtypes [[CGMP-specific phosphodiesterase type 5|PDE5]], [[PDE6]], [[PDE9]] and [[PDE11]].  [[IC50|IC<sub>50</sub>]] values are 0.76, 0.15, 29.0, and 12.0 ''μ''M, respectively.<ref>{{Cite journal 
| last1 = Taniguchi | first1 = Y. 
| last2 = Tonaikachi | first2 = H. 
| last3 = Shinjo | first3 = K. 
| doi = 10.1016/j.febslet.2006.08.015 
| title = Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35 
| journal = FEBS Letters 
| volume = 580 
| issue = 21 
| pages = 5003–5008 
| year = 2006 
| pmid = 16934253 
| pmc = 
}}</ref><ref>{{Cite journal 
| last1 = Keswani | first1 = A. N. 
| last2 = Peyton | first2 = K. J. 
| last3 = Durante | first3 = W. 
| last4 = Schafer | first4 = A. I. 
| last5 = Tulis | first5 = D. A. 
| title = The Cyclic GMP Modulators YC-1 and Zaprinast Reduce Vessel Remodeling Through Antiproliferative and Proapoptotic Effects 
| doi = 10.1177/1074248409333266 
| journal = Journal of Cardiovascular Pharmacology and Therapeutics 
| volume = 14 
| issue = 2 
| pages = 116–124 
| year = 2009 
| pmid = 19342499 
| pmc =2702762 
}}</ref>

Zaprinast inhibits the growth of asexual blood-stage [[malaria]] parasites ([[Plasmodium falciparum|''P. falciparum'']]) ''in vitro'' with an [[ED-50|ED<sub>50</sub>]] value of 35 ''μ''M, and inhibits PfPDE1, a ''[[P. falciparum]]'' cGMP-specific phosphodiesterase, with an IC<sub>50</sub> value of 3.8 ''μ''M.<ref>{{Cite journal|title = PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum|author1=Keizo Yuasa |author2=Fumika Mi-Ichi |author3=Tamaki Kobayashi |author4=Masaya Yamanouchi |author5=Jun Kotera |author6=Kiyoshi Kita |author7=Kenji Omori |date = 2005|journal = Biochem. J.|doi = 10.1042/BJ20050425|pmid = 16038615|pmc=1317681|volume=392|pages=221–9}}</ref>

Zaprinast has also been shown to activate the orphan [[G-protein coupled receptor]] known as [[GPR35]], both in rats and humans,<ref>{{cite journal|journal = FEBS Letters|title = Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35|author1=Yasuhito Taniguchi |author2=Hiroko Tonai-Kachi |author3=Katsuhiro Shinjo |volume = 580|issue = 21|pages = 5003–5008|year = 2006|doi=10.1016/j.febslet.2006.08.015|pmid=16934253}}</ref> however, the clinical significance of this has yet to be determined.

==References==
{{reflist}}

{{Phosphodiesterase inhibitors}}

[[Category:Abandoned drugs]]
[[Category:Phosphodiesterase inhibitors]]
[[Category:PDE5 inhibitors]]


{{pharma-stub}}